Lucid Diagnostics Executes First Direct Employer Contract To Provide Ancira Auto Group EsoGuard Esophageal Precancer Testing As An Employee Benefit
Portfolio Pulse from Happy Mohamed
Lucid Diagnostics (NASDAQ:LUCD), a subsidiary of PAVmed Inc. (NASDAQ:PAVM), has signed its first direct employer contract with Ancira Auto Group to provide EsoGuard esophageal precancer testing as an employee benefit. The three-year contract is part of Lucid's strategic initiative to expand patient access to EsoGuard testing across multiple commercial channels. The testing will be performed at Ancira locations across the San Antonio metropolitan area, with analysis conducted at Lucid's CLIA-certified laboratory in Lake Forest, California.
August 24, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics has signed a contract with Ancira Auto Group to provide EsoGuard testing as an employee benefit. This is part of Lucid's strategy to expand access to its testing services.
The contract with Ancira Auto Group represents a new revenue stream for Lucid Diagnostics and a strategic move to expand the reach of its EsoGuard testing services. This could potentially boost the company's revenues and profitability in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
PAVmed, the parent company of Lucid Diagnostics, could potentially benefit from Lucid's contract with Ancira Auto Group to provide EsoGuard testing as an employee benefit.
As the parent company of Lucid Diagnostics, PAVmed could potentially benefit from the increased revenues and profitability that may result from Lucid's contract with Ancira Auto Group. This could have a positive impact on PAVmed's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 75